Subscribe To
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financing potentially available increased to $300 million Commercial launches in H. pylori, and Erosive Esophagitis […] The post Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business U...
Read More
Posted: Nov 8 2022, 22:00
Author Name: forextv
Views: 111486